Versuchen Sie es noch einmal mit einem anderen Suchbegriff
Ziel des Fonds ist der Kapitalerhalt und die Erwirtschaftung eines langfristigen Kapitalzuwachses durch weltweite Anlagen in die Aktien von Unternehmen in den Sektoren Biotechnologie, Diagnostik und Life - Science - Instrumenten.
Name | Titel | Seit | Bis |
---|---|---|---|
David Pinniger | Portfolio Manager | 2013 | Aktuell |
Biografie | David Pinniger joined Polar Capital in August 2013 as lead manager of the Biotechnology Fund within the healthcare team. Prior to joining Polar Capital, for five years David was portfolio manager of the International Biotechnology Trust at SV Life Sciences. He also previously spent three years working at venture capital firm Abingworth as an analyst managing biotechnology investments held across the firm’s venture and specialist funds, and four years at Morgan Stanley as an analyst covering the European pharmaceuticals and biotechnology sector. David received a first class honours degree in human sciences from Oxford University in 1999 and is a CFA charterholder. | ||
Gareth Powell | Portfolio Manager | 2013 | Aktuell |
Biografie | Gareth Powell joined Polar Capital in 2007 to establish the healthcare investment team. He is joint manager of the Healthcare Opportunities Fund. He joined Framlington in 1999, later becoming a portfolio manager on the Framlington Health Fund. In 2002, Gareth helped launch the Framlington Biotech Fund, which he managed until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder. | ||
Daniel Mahony | Portfolio Manager | 2013 | 2019 |
Biografie | Daniel Mahony Ph.D. joined Polar Capital to establish the healthcare investment team in 2007. He is joint manager of the Healthcare Opportunities Fund and lead manager of the Healthcare Blue Chip Fund. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley, covering the European biotechnology, medical technology and healthcare services sectors. He also previously worked in New York for ING Barings Furman Selz following the US biotechnology sector. Before working in the investment field, Daniel worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California. Daniel received his PhD from Cambridge University in 1995 and a first class honours degree in biochemistry from Oxford University in 1991. |
Sind Sie sicher, dass Sie %USER_NAME% sperren möchten?
Dadurch werden Sie und %USER_NAME% nicht mehr in der Lage sein, Beiträge des jeweils anderen auf Investing.com zu sehen.
%USER_NAME% wurde erfolgreich zu Ihrer Sperrliste hinzugefügt.
Da Sie diese Person entsperrt haben, müssen Sie 48 Stunden warten, bevor Sie sie wieder sperren können.
Sagen Sie uns Ihre Meinung zu diesem Kommentar
Vielen Dank!
Ihre Meldung wurde zur Überprüfung an unsere Moderatoren geschickt